Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

Candel Therapeutics, Inc. has reported positive final survival data from a phase 2 clinical trial assessing CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic cancer, positive survival data showed notable improvement in estimated median overall survival ...

"PanTher Therapeutics launches second trial for chemotherapy patch" was originally created and published by Medical Device Network, a GlobalData owned brand.

PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC) ...

A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.

The open-label Phase 2 trial enrolled 48 patients in the mITT population with non-resectable locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC) across the ...

Zhang, J., et al. (2024). The role of the aging process and related factor EMP1 in promoting progression of resectable pancreatic cancer. Genes & Diseases. doi.org/10.1016/j.gendis.2024.101490.

Prognostic implication of body composition changes in patients with borderline resectable/locally advanced pancreatic adenocarcinoma (PDAC) treated with mFOLFIRINOX. Authors: Jong Hyuk Lee, Hyehyun ...

Source Reference: Reyngold M, et al "Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy" JAMA Oncol 2025; DOI: 10.1001/jamaoncol.2025.0460.

On January 24, 2008, as part of the 2008 Gastrointestinal Cancers Symposium (Orlando, Florida), a 1-day consensus conference was held on resectable and borderline resectable pancreatic adenocarcinoma.